Cellectis S.A.
CLLSDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CLLS Earnings Report
FQ end 2026-06
UCART22
B-cell Acute Lymphoblastic Leukemia
UCART20x22
B-cell Non-Hodgkin Lymphoma (B-NHL)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UCART22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | - | - |
UCART20x22 | Phase 2 | B-cell Non-Hodgkin Lymphoma (B-NHL) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cellectis S.A.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Cellectis S.A.'s (CLLS) pipeline across Phase 2. Its lead program is UCART22 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cellectis S.A.'s next FDA catalyst?→
Cellectis S.A.'s (CLLS) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLLS biotech catalysts?→
Add CLLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cellectis S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.